+

PE20060378A1 - Regimenes y kits de progestina ciclica - Google Patents

Regimenes y kits de progestina ciclica

Info

Publication number
PE20060378A1
PE20060378A1 PE2005000783A PE2005000783A PE20060378A1 PE 20060378 A1 PE20060378 A1 PE 20060378A1 PE 2005000783 A PE2005000783 A PE 2005000783A PE 2005000783 A PE2005000783 A PE 2005000783A PE 20060378 A1 PE20060378 A1 PE 20060378A1
Authority
PE
Peru
Prior art keywords
progestin
regimes
kits
cyclic
administration
Prior art date
Application number
PE2005000783A
Other languages
English (en)
Inventor
Gary Sondermann Grubb
Ginger Dale Constantine
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35064935&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20060378(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of PE20060378A1 publication Critical patent/PE20060378A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE REFIERE A UN REGIMEN DE ADMINISTRACION QUE COMPRENDE: A) UNA PRIMERA FASE DE ADMINISTRACION DE 21-27 UNIDADES DE DOSIFICACION DIARIA CONTENIENDO UNA PROGESTINA SELECCIONADA ENTRE 17-HIDROXIPROGESTERONA, ESTERES DE 19-NOR-TESTOSTERONA, NORETINDRONA, DIDROGESTERONA, TANAPROGET, ENTRE OTROS; B) UNA SEGUNDA FASE DE ADMINISTRACION QUE COMPRENDE 1-7 DIAS DE UN PLACEBO. REFERIDA TAMBIEN A UN KIT DE ADMINISTRACION ORAL O DE LIBERACION PROLONGADA TAL COMO TRANSDERMICO, TRANSMUCOSAL O TRANSVAGINAL UTILES PARA LA ANTICONCEPCION
PE2005000783A 2004-07-07 2005-07-06 Regimenes y kits de progestina ciclica PE20060378A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US58604504P 2004-07-07 2004-07-07

Publications (1)

Publication Number Publication Date
PE20060378A1 true PE20060378A1 (es) 2006-06-02

Family

ID=35064935

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005000783A PE20060378A1 (es) 2004-07-07 2005-07-06 Regimenes y kits de progestina ciclica

Country Status (14)

Country Link
US (3) US20060009428A1 (es)
EP (1) EP1773344A1 (es)
JP (2) JP5288796B2 (es)
CN (2) CN104208067A (es)
AR (1) AR049707A1 (es)
AU (1) AU2005269938A1 (es)
BR (1) BRPI0512991A (es)
CA (1) CA2571377C (es)
MX (1) MXPA06014579A (es)
PA (1) PA8638601A1 (es)
PE (1) PE20060378A1 (es)
SV (1) SV2006002165A (es)
TW (1) TW200603813A (es)
WO (1) WO2006014476A1 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6391907B1 (en) * 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
US6509334B1 (en) * 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
UA73119C2 (en) * 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
PE20060378A1 (es) 2004-07-07 2006-06-02 Wyeth Corp Regimenes y kits de progestina ciclica
GT200500185A (es) * 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
ATE460937T1 (de) * 2005-04-28 2010-04-15 Wyeth Corp Mikronisierte tanaproget zusammensetzungen und verfahren zu ihrer herstellung
ES2327783T3 (es) * 2005-04-28 2009-11-03 Wyeth Composiciones que contienen tanaproget micronizado.
BRPI0610431A2 (pt) * 2005-04-28 2012-10-23 Wyeth Corp composição farmacêutica, processo para preparar uma composição, cápsula, e, kit farmacêutico
EP1893217A2 (en) * 2005-06-09 2008-03-05 Wyeth a Corporation of the State of Delaware Tanaproget compositions containing ethinyl estradiol
US10137135B2 (en) 2005-08-15 2018-11-27 Allergan Sales, Llc Formulations and methods for providing progestin-only contraception while minimizing adverse side effects associated therewith
US20070093548A1 (en) * 2005-10-25 2007-04-26 Wyeth Use of progesterone receptor modulators
DE102006050558B4 (de) 2006-10-26 2009-03-26 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System enthaltend Norelgestromin zur Kontrazeption und Hormonsubstitution
JP2011507853A (ja) 2007-12-20 2011-03-10 テバ ウィメンズ ヘルス インコーポレイテッド 緊急避妊のための投与量レジメンならびに薬学的組成物およびパッケージ
DE102008022221A1 (de) * 2008-05-06 2009-11-12 Universität des Saarlandes Inhibitoren der humanen Aldosteronsynthase CYP11B2
US9198876B2 (en) 2008-10-08 2015-12-01 Agile Therapeutics, Inc. Contraceptive transdermal delivery of hormones
CA2740004A1 (en) 2008-10-08 2010-04-15 Agile Therapeutics, Inc. Transdermal delivery
US9198919B2 (en) 2008-10-08 2015-12-01 Agile Therapeutics, Inc. Contraceptive transdermal delivery of hormones
CA2756222A1 (en) 2009-03-27 2010-09-30 Agile Therapeutics, Inc. Transdermal delivery
BR112012019725A2 (pt) * 2010-02-08 2020-11-10 Tao Tom Du usos de uma composição farmacêutica e uso de pelo menos um progestogênio
US10849857B2 (en) 2010-07-28 2020-12-01 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
AR081670A1 (es) 2010-06-29 2012-10-10 Leon Farma Sa Lab Composicion farmaceutica que comprende drospirenona y kit anticonceptivo
US11351122B1 (en) 2010-07-28 2022-06-07 Laboratorios Leon Farma Sa Synthetic progestogens and pharmaceutical compositions comprising the same
RS62297B1 (sr) 2011-11-23 2021-09-30 Therapeuticsmd Inc Prirodne kombinovane hormonske supstitucione formulacije i terapije
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
EP2730284A1 (en) * 2012-11-12 2014-05-14 Naari AG Levonorgestrel-only-composition for optimized oral contraception with defined levonorgestrel content, dosage regimen and pharmaceutical preparation
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
KR20170005819A (ko) 2014-05-22 2017-01-16 쎄러퓨틱스엠디, 인코퍼레이티드 천연 복합 호르몬 대체 제형 및 요법
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
JP2019513709A (ja) 2016-04-01 2019-05-30 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． ステロイドホルモン薬学的組成物
CN107982520A (zh) * 2017-12-25 2018-05-04 上海交通大学医学院附属第九人民医院 外源性MPA与hMG在制备动物模型药物中的应用
US11679114B2 (en) 2021-07-26 2023-06-20 Navad Life Sciences Pte Progestogen-only oral contraception
WO2024218800A1 (en) * 2023-04-21 2024-10-24 Akums Drugs And Pharmaceuticals Limited Vaginal drug delivery system of dydrogesterone

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU581486B2 (en) * 1985-12-30 1989-02-23 Warner-Lambert Company Graduated estrogen contraceptive
EP0559240B1 (en) * 1987-09-24 2001-12-05 Jencap Research Limited Contraceptive packages containing oestrogen and progestin
ES2223081T3 (es) 1996-07-26 2005-02-16 Wyeth Metodo anticonceptivo oral monofasico y kit que comprende una combinacion de progestina y estrogeno.
WO2001030355A1 (fr) * 1999-10-25 2001-05-03 Laboratoire Theramex Medicament contraceptif a base d'un progestatif et d'un estrogene et son mode de preparation
AU4134599A (en) * 1998-04-07 1999-10-25 Akzo Nobel N.V. Progestogen-only contraceptive kit
US6444668B1 (en) * 1999-05-04 2002-09-03 Wyeth Combination regimens using progesterone receptor modulators
US6407101B1 (en) * 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
PL351083A1 (en) * 1999-05-04 2003-03-10 American Home Prod Cyclothiocarbamate derivatives as progesterone receptor modulators
US6509334B1 (en) 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
EE200200103A (et) * 1999-08-31 2003-04-15 Jenapharm Gmbh & Co. Kg Mesoprogestiinid (progesterooniretseptori modulaatorid) naise kontratseptiivide komponendina
UA73119C2 (en) * 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
MXPA04012420A (es) * 2002-06-25 2005-04-19 Wyeth Corp Derivados de ciclotiocabamativa como moduladores de rp y uso de los mismos para tratamiento de trastornos de la piel.
GT200500186A (es) 2004-07-07 2006-03-02 Regimenes anticonceptivos con antagonistas del receptor de progesterona y kits
PE20060378A1 (es) 2004-07-07 2006-06-02 Wyeth Corp Regimenes y kits de progestina ciclica
GT200500183A (es) 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
GT200500185A (es) 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos

Also Published As

Publication number Publication date
AR049707A1 (es) 2006-08-30
CN1980676A (zh) 2007-06-13
JP5288796B2 (ja) 2013-09-11
EP1773344A1 (en) 2007-04-18
CA2571377A1 (en) 2006-02-09
MXPA06014579A (es) 2007-03-01
PA8638601A1 (es) 2006-07-03
CA2571377C (en) 2014-03-25
US8604027B2 (en) 2013-12-10
SV2006002165A (es) 2006-05-09
TW200603813A (en) 2006-02-01
JP2013040181A (ja) 2013-02-28
AU2005269938A1 (en) 2006-02-09
CN104208067A (zh) 2014-12-17
WO2006014476A1 (en) 2006-02-09
US20140094458A1 (en) 2014-04-03
BRPI0512991A (pt) 2008-04-22
JP2008505909A (ja) 2008-02-28
US20100292198A1 (en) 2010-11-18
US20060009428A1 (en) 2006-01-12

Similar Documents

Publication Publication Date Title
PE20060378A1 (es) Regimenes y kits de progestina ciclica
DK1768625T3 (da) Sammensætninger med vedvarende frigørelse indeholdende progesteron-receptormodulatorer
CL2007002228A1 (es) Composicion farmaceutica topica que comprende 1-(2-metilpropil)-1h-imidazo[4,5-c]quinolin-4-amina; composiicon empacada; metodos para esterelizarlas; util para cicatrizar tejido donde la dermis se ha desgarrado.
MX391854B (es) Formulaciones farmaceuticas que contienen hidrato de propilenglicol de dapagliflozina
GT200600200A (es) Composicion farmaceutica que contienen gestagenos y/o estrogenos y 5-metil-(6s)-tetrahidrofolato
CL2009001766A1 (es) Composicion farmaceutica solida para administracion oral que comprende: un taxano sustancialmente amorfo definido, un portador hidrofilico definido y un tensoactivo definido; metodo para preparar la composicion; y su uso para tratar una enfermedad neoplasica.
HN2004000490A (es) Procedimiento para la preparacion de una composicion farmaceutica solida administrable oralmente
EA200901319A1 (ru) Композиции для назального введения
CL2007002095A1 (es) Composicion farmaceutica topica que comprende 1-(2-metilpropil)-1h-imidazo[4,5-c]quinolin-4-amina; composicion empacada; metodo para esterilizarla; util para cicatrizar tejido donde la dermis se ha desgarrado.
AR058175A1 (es) Composiciones farmaceuticas solidas que contienen pregabalina
BR112012018670A2 (pt) combinação, uso de um composto, composição farmacêutica, e, pacote de paciente
DK2114383T3 (da) Små-volumen orale transmukosale doseringsformer indeholdende sufentanil til behandling af smerte
GT200900023A (es) Formas farmacéuticas de dosificación oral que contienen un analgésico opioide.
MA30207B1 (fr) Modulateurs des recepteurs de la progesterone a base d'indole sulfonamide
PE20060485A1 (es) Regimenes anticonceptivos con antagonistas del receptor de progesterona y kits
EA200702102A1 (ru) Пластинки, содержащие стероидные гормоны
EA201071218A1 (ru) Улучшенные композиции для активных фармацевтических компонентов с плохой проницаемостью
CY1115064T1 (el) Διαδερμικο συστημα παραδοσης ορμονων χωρις ενισχυτες διεισδυσης
MX2012005689A (es) Analogos de acido araquidonico y metodos para el tratamiento analgesico utilizando los mismos.
BR0311189A (pt) Composições farmacêuticas contendo polimorfo a de flibanserin
PE20060275A1 (es) Composicion farmaceutica que contiene progestina y estrogeno para el tratamiento de trastorno disforico premenstrual
PE20081895A1 (es) Regimen anticonceptivo oral
BR122016006880B8 (pt) forma de dosagem contendo pantoprazol como ingrediente ativo
DK1414467T3 (da) Topisk behandling af mastalgi
NO20065898L (no) 1-heterocyklyl-1,5-dihydro-pyrido[3,2-b]indol-2-oner

Legal Events

Date Code Title Description
FA Abandonment or withdrawal
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载